New rules for medicines: RPI 2025 and their effects on pharmacies!

New rules for medicines: RPI 2025 and their effects on pharmacies!

Wiedner Hauptstraße 63, 1040 Wien, Österreich - On April 29, 2025, an important step in the pension supply in Austria was taken. From May 2025, the reformed guidelines will come into force on the delivery of in parallel imported drug specialties (RPI 2025). These new regulations offer clear legal framework conditions that benefit the parallel importers in particular.

The new guidelines developed in cooperation with the Austrian Chamber of Pharmacists promise numerous advantages for everyone involved. However, pharmacies have to meet specific prerequisites in order to enable social security to be offset. This is intended to ensure that the patients are reliably supplied with the required medicines.

advantages of the RPI 2025

The RPI 2025 bring significant administrative facilities and cost savings for social security, since they significantly reduce the administrative effort in the calculation and billing of medication. An innovative threshold of 3 euros for taxes leads to less bureaucracy and optimized processing. Claudia Neumayer stickler, the chairwoman of the conference of social security institutions, emphasizes the importance of these new regulations for the seamless care of the insured.

The RPI 2025 are a further development of the RPI 2024, which has been in force since July 2024. Before the introduction of these regulations, the taxes for parallel -imported drug specialties had led to additional costs for social security. The new guidelines should now actively prevent this.

Important aspects of parallel imports

parallel imports must meet the provisions of the Medicines Act. This law ensures that pharmaceutical specialties are approved or registered in Austria to ensure a secure delivery. According to the specifications, evidence of the non -availability of medication in large pharmaceutical retailers must be obtained. This applies in particular if the drug specialty or all -imported variants are not available. RIS explains this in detail, in detail, Especially with regard to the Direct to Pharmacy sales model, where proof of the non -availability is required by the company authorized.

For the use of parallel imports, it is also necessary to adhere to the provisions in Section 10c of the Medicines Act. Information on the approval procedure and the forms required for this can be found on the BASG website, where FAQs and further information can also be provided BASG .

summarized, the new guidelines promise a significant improvement in pharmaceutical supply in Austria about the delivery of parallel of imported drug specialties. They not only promote the efficiency of pharmacies, but also the cost control of social security, which ultimately supports the goal of comprehensive and reliable patient care.